30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Onkure Therapeutics Inc (OKUR)

Track

Over the last 90 days, Onkure Therapeutics Inc. has seen two insider transactions, both classified as planned sales, totaling $1,710,160.7. The President and CEO, Nicholas Saccomano, and CFO, Jason Leverone, were involved in these sales. The company's stock has experienced an 8.8% increase in the past 90 days.
Stock chart
Ticker: OKUR Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Saccomano Nicholas A
President and CEO
1 sale — total 100,000 USD
Planned sale 22 Jun 2026
Value US$3,859,985.80 | Price 393.65 | Shares 63,680
Planned sale 22 Jun 2026
Value US$306,292.90 | Price 63.93 | Shares 56,795
Sale 23 Mar 2026
Value US$1,251.11 | Price 4.16 | Shares 301
Sale 23 Mar 2026
Value US$357.46 | Price 4.16 | Shares 86
Planned sale 22 Dec 2025
Value US$258.19 | Price 2.97 | Shares 87
Planned sale 22 Dec 2025
Value US$896.25 | Price 2.97 | Shares 302
Sale 22 Sep 2025
Value US$794.92 | Price 2.62 | Shares 303
Sale 22 Sep 2025
Value US$230.87 | Price 2.62 | Shares 88
Sale 23 Jun 2025
Value US$209.81 | Price 2.38 | Shares 88
Sale 23 Jun 2025
Value US$722.41 | Price 2.38 | Shares 303
Sale 15 May 2025
Value US$3,363,022.63 | Price 1.85 | Shares 1,813,439
Buy 15 May 2025
Value US$2,090,000.50 | Price 1.85 | Shares 1,129,730
Buy 15 May 2025
Value US$499,999.50 | Price 1.85 | Shares 270,270
Sale 12 May 2025
Value US$48,235.50 | Price 1.99 | Shares 24,300
Sale 7 Apr 2025
Value US$1,378.24 | Price 2.67 | Shares 516
Sale 7 Apr 2025
Value US$4,925.32 | Price 2.67 | Shares 1,844
Sale 4 Apr 2025
Value US$1,191.28 | Price 3.33 | Shares 358
Sale 4 Apr 2025
Value US$4,252.67 | Price 3.33 | Shares 1,278
Buy 25 Sep 2024
Value US$102,871.51 | Price 1.50 | Shares 68,746
Buy 24 Sep 2024
Value US$41,866.24 | Price 1.41 | Shares 29,600
Buy 18 Sep 2024
Value US$1,128.40 | Price 1.40 | Shares 806
Buy 17 Sep 2024
Value US$75,108.46 | Price 1.36 | Shares 55,300
Buy 16 Sep 2024
Value US$236,870.69 | Price 1.37 | Shares 172,747
Buy 13 Sep 2024
Value US$196,950.00 | Price 1.31 | Shares 150,000
Buy 12 Sep 2024
Value US$50,523.40 | Price 1.40 | Shares 36,176
Buy 14 Aug 2024
Value US$142,008.23 | Price 1.41 | Shares 100,487
Buy 13 Aug 2024
Value US$238,589.56 | Price 1.39 | Shares 171,339
Buy 14 May 2024
Value US$515,900.00 | Price 1.54 | Shares 335,000
Buy 14 May 2024
Value US$123,678.36 | Price 1.56 | Shares 79,281
Sale 28 Aug 2023
Value US$98,057.81 | Price 6.28 | Shares 15,625
Proposed sale 28 Aug 2023
Value US$98,057.77 | Price 6.28 | Shares 15,625
Proposed sale 23 Jun 2023
Value US$735,000.00 | Price 7.35 | Shares 100,000
Sale 23 Jun 2023
Value US$709,740.00 | Price 7.10 | Shares 100,000
Buy 8 May 2023
Value US$1,000,000.00 | Price 8.00 | Shares 125,000
Buy 1 Sep 2022
Value US$25,447.50 | Price 3.39 | Shares 7,500
Buy 31 Aug 2022
Value US$10,307.31 | Price 3.21 | Shares 3,212
Buy 30 Aug 2022
Value US$5,892.56 | Price 3.19 | Shares 1,845
Buy 30 Aug 2022
Value US$3,081.00 | Price 3.16 | Shares 975
Buy 29 Aug 2022
Value US$3,693.60 | Price 3.24 | Shares 1,140
Planned buy 29 Aug 2022
Value US$268.92 | Price 3.24 | Shares 83
Buy 23 Jun 2021
Value US$192,244.72 | Price 9.28 | Shares 20,710
Buy 22 Jun 2021
Value US$127,486.64 | Price 8.72 | Shares 14,615
Buy 21 Jun 2021
Value US$294,927.10 | Price 9.03 | Shares 32,659
Buy 4 Jun 2021
Value US$2,422.02 | Price 9.42 | Shares 257
Buy 3 Jun 2021
Value US$111,943.15 | Price 9.25 | Shares 12,100
Buy 28 May 2021
Value US$133.00 | Price 9.50 | Shares 14
Buy 13 Apr 2021
Value US$3,000,000.00 | Price 15.00 | Shares 200,000
Buy 13 Apr 2021
Value US$9,999,990.00 | Price 15.00 | Shares 666,666
Buy 13 Apr 2021
Value US$9,999,990.00 | Price 15.00 | Shares 666,666
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-24 2026-06-22 PlS Planned sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
63,680 -3.4%
393.65
US$3,859,986 		63,680 -3.4% 393.65 US$3,859,986
2026-06-24 2026-06-22 PlS Planned sale
3.6
Leverone Jason A.

Chief Financial Officer

Officer
56,795 +3.9%
63.93
US$306,293 		56,795 +3.9% 63.93 US$306,293
2026-03-24 2026-03-23 S Sale
3.6
Leverone Jason A.

Chief Financial Officer

Officer
52,482 -11.1%
307.58
US$3,346,311 		52,482 -11.1% 307.58 US$3,346,311
2026-03-24 2026-03-23 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
86 -1.2%
4.16
US$357 		86 -1.2% 4.16 US$357
2025-12-23 2025-12-22 PlS Planned sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
87 -1.2%
2.97
US$258 		87 -1.2% 2.97 US$258
2025-12-23 2025-12-22 PlS Planned sale
3.6
Leverone Jason A.

Chief Financial Officer

Officer
302 -1.8%
2.97
US$896 		302 -1.8% 2.97 US$896
2025-09-24 2025-09-22 S Sale
3.6
Leverone Jason A.

Chief Financial Officer

Officer
303 -2.3%
2.62
US$795 		303 -2.3% 2.62 US$795
2025-09-24 2025-09-22 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
88 -2.4%
2.62
US$231 		88 -2.4% 2.62 US$231
2025-06-25 2025-06-23 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
88 -2.4%
2.38
US$210 		88 -2.4% 2.38 US$210
2025-06-25 2025-06-23 S Sale
3.6
Leverone Jason A.

Chief Financial Officer

Officer
303 -2.3%
2.38
US$722 		303 -2.3% 2.38 US$722
2025-05-19 2025-05-15 S Sale
3.8
Cormorant Asset Management, LP

Former 10% Owner
1,813,439 -100.0%
1.85
US$3,363,023 		1,813,439 -100.0% 1.85 US$3,363,023
2025-05-19 2025-05-15 B Purchase
3.2
ACORN BIOVENTURES, L.P.
Large shareholder
1,129,730 +inf%
1.85
US$2,090,000 		1,129,730 +inf% 1.85 US$2,090,000
2025-05-19 2025-05-15 B Purchase
3.2
ACORN BIOVENTURES, L.P.
Large shareholder
270,270 +18.8%
1.85
US$500,000 		270,270 +18.8% 1.85 US$500,000
2025-05-14 2025-05-12 S Sale
3.8
Cormorant Asset Management, LP
Large shareholder
24,300 -1.3%
1.99
US$48,236 		24,300 -1.3% 1.99 US$48,236
2025-04-08 2025-04-07 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
516 -12.3%
2.67
US$1,378 		516 -12.3% 2.67 US$1,378
2025-04-08 2025-04-07 S Sale
3.6
Leverone Jason A.

Chief Financial Officer

Officer
1,844 -12.3%
2.67
US$4,925 		1,844 -12.3% 2.67 US$4,925
2025-04-08 2025-04-04 S Sale
3.6
Saccomano Nicholas A

President and CEO

Executive Director
358 -7.9%
3.33
US$1,191 		358 -7.9% 3.33 US$1,191
2025-04-08 2025-04-04 S Sale
3.6
Leverone Jason A.

Chief Financial Officer

Officer
1,278 -7.8%
3.33
US$4,253 		1,278 -7.8% 3.33 US$4,253
2024-09-26 2024-09-25 B Purchase
2.9
Leonard Braden Michael
Large shareholder
68,746 +2.0%
1.50
US$102,872 		68,746 +2.0% 1.50 US$102,872
2024-09-26 2024-09-24 B Purchase
2.9
Leonard Braden Michael
Large shareholder
29,600 +0.9%
1.41
US$41,866 		29,600 +0.9% 1.41 US$41,866
2024-09-19 2024-09-18 B Purchase
2.9
Leonard Braden Michael
Large shareholder
806 +0.0%
1.40
US$1,128 		806 +0.0% 1.40 US$1,128
2024-09-19 2024-09-17 B Purchase
2.9
Leonard Braden Michael
Large shareholder
55,300 +1.7%
1.36
US$75,108 		55,300 +1.7% 1.36 US$75,108
2024-09-16 2024-09-16 B Purchase
2.9
Leonard Braden Michael
Large shareholder
172,747 +5.5%
1.37
US$236,871 		172,747 +5.5% 1.37 US$236,871
2024-09-16 2024-09-13 B Purchase
2.9
Leonard Braden Michael
Large shareholder
150,000 +5.0%
1.31
US$196,950 		150,000 +5.0% 1.31 US$196,950
2024-09-16 2024-09-12 B Purchase
2.9
Leonard Braden Michael
Large shareholder
36,176 +1.2%
1.40
US$50,523 		36,176 +1.2% 1.40 US$50,523
2024-08-14 2024-08-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
100,487 +3.5%
1.41
US$142,008 		100,487 +3.5% 1.41 US$142,008
2024-08-14 2024-08-13 B Purchase
2.9
Leonard Braden Michael
Large shareholder
171,339 +6.4%
1.39
US$238,590 		171,339 +6.4% 1.39 US$238,590
2024-05-16 2024-05-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
335,000 +14.3%
1.54
US$515,900 		335,000 +14.3% 1.54 US$515,900
2024-05-16 2024-05-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
79,281 +3.5%
1.56
US$123,678 		79,281 +3.5% 1.56 US$123,678
2023-08-29 2023-08-28 S Sale
2.2
Hall Ashley

Chief Development Officer

Officer
15,625 -28.3%
6.28
US$98,058 		15,625 -28.3% 6.28 US$98,058
2023-08-28 2023-08-28 PrS Proposed sale
2.2
Hall Ashley

Officer

Officer
15,625
6.28
US$98,058 		15,625 6.28 US$98,058
2023-06-23 2023-06-23 PrS Proposed sale
2.3
Novo Holdings A/S

10% Stockholder

Large shareholder
100,000
7.35
US$735,000 		100,000 7.35 US$735,000
2023-06-23 2023-06-23 S Sale
2.3
Novo Holdings A/S
Large shareholder
100,000 -2.9%
7.10
US$709,740 		100,000 -2.9% 7.10 US$709,740
2023-05-10 2023-05-08 B Purchase
1.8
O'Donnell Niall
Non-Executive Director
125,000 +6.1%
8.00
US$1,000,000 		125,000 +6.1% 8.00 US$1,000,000
2022-09-02 2022-09-01 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
7,500 +121.0%
3.39
US$25,448 		7,500 +121.0% 3.39 US$25,448
2022-08-31 2022-08-31 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
3,212 +107.6%
3.21
US$10,307 		3,212 +107.6% 3.21 US$10,307
2022-08-31 2022-08-30 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
1,845 +161.8%
3.19
US$5,893 		1,845 +161.8% 3.19 US$5,893
2022-08-31 2022-08-30 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
975 +3.2%
3.16
US$3,081 		975 +3.2% 3.16 US$3,081
2022-08-31 2022-08-29 B Purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
1,140 +inf%
3.24
US$3,694 		1,140 +inf% 3.24 US$3,694
2022-08-31 2022-08-29 PP Planned purchase
1.4
Cruse Michael

Chief Operating Officer

Officer
83 +0.3%
3.24
US$269 		83 +0.3% 3.24 US$269
2021-06-25 2021-06-23 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
20,710 +1.1%
9.28
US$192,245 		20,710 +1.1% 9.28 US$192,245
2021-06-23 2021-06-22 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
14,615 +0.8%
8.72
US$127,487 		14,615 +0.8% 8.72 US$127,487
2021-06-23 2021-06-21 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
32,659 +1.7%
9.03
US$294,927 		32,659 +1.7% 9.03 US$294,927
2021-06-07 2021-06-04 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
257 +0.0%
9.42
US$2,422 		257 +0.0% 9.42 US$2,422
2021-06-07 2021-06-03 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
12,100 +0.6%
9.25
US$111,943 		12,100 +0.6% 9.25 US$111,943
2021-06-02 2021-05-28 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
14 +0.0%
9.50
US$133 		14 +0.0% 9.50 US$133
2021-04-15 2021-04-13 B Purchase
1.5
Muralidhar Bali
Non-Executive Director
200,000 +12.1%
15.00
US$3,000,000 		200,000 +12.1% 15.00 US$3,000,000
2021-04-15 2021-04-13 B Purchase
3.0
New Enterprise Associates 15, L.P.
Large shareholder
666,666 +16.2%
15.00
US$9,999,990 		666,666 +16.2% 15.00 US$9,999,990
2021-04-14 2021-04-13 B Purchase
2.3
Novo Holdings A/S
Large shareholder
666,666 +24.1%
15.00
US$9,999,990 		666,666 +24.1% 15.00 US$9,999,990
Explore more

More insider trading research around Onkure Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America